Pro-Dex (NASDAQ:PDEX) Price Target Raised to $80.00

Pro-Dex (NASDAQ:PDEX – Free Report) had its price objective hoisted by Ascendiant Capital Markets from $74.00 to $80.00 in a research report report published on Monday morning,Benzinga reports. They currently have a buy rating on the medical instruments supplier’s stock.

A number of other brokerages also recently commented on PDEX. Zacks Research downgraded shares of Pro-Dex from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 9th. Weiss Ratings upgraded shares of Pro-Dex from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Tuesday, November 10th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, Pro-Dex has a consensus rating of “Moderate Buy” and an average price target of $80.00.

Get Our Latest Stock Analysis on Pro-Dex

Pro-Dex Trading Up 3.2%

NASDAQ:PDEX opened at $63.94 on Monday. Pro-Dex has a 12-month low of $28.81 and a 12-month high of $77.00. The company has a current ratio of 4.19, a quick ratio of 2.49 and a debt-to-equity ratio of 0.25. The stock’s 50 day simple moving average is $64.84 and its 200-day simple moving average is $58.03. The firm has a market cap of $204.61 million, a P/E ratio of 16.97 and a beta of 0.12.

Pro-Dex (NASDAQ:PDEX – Get Free Report) last issued its quarterly earnings results on Thursday, October 29th. The medical instruments supplier reported $0.92 earnings per share for the quarter, topping the consensus estimate of $0.67 by $0.25. Pro-Dex had a return on equity of 26.18% and a net margin of 15.12%. The firm had revenue of $20.56 million during the quarter, compared to the consensus estimate of $20.40 million. Equities analysts anticipate that Pro-Dex will post 3.09 EPS for the current year.

Insider Buying and Selling

In related news, CFO Alisha Charlton sold 2,300 shares of the company’s stock in a transaction that occurred on Wednesday, September 9th. The stock was sold at an average price of $61.30, for a total value of $140,990.00. Following the sale, the chief financial officer owned 21,870 shares in the company, valued at $1,340,631. This represents a 9.52% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Kirk Richard Lee Van, Jr. sold 765 shares of the firm’s stock in a transaction that occurred on Friday, September 11th. The shares were sold at an average price of $59.36, for a total value of $45,410.40. Following the completion of the transaction, the chief executive officer directly owned 79,228 shares of the company’s stock, valued at $4,702,974.08. The trade was a 0.96% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 22,300 shares of company stock valued at $1,351,657. Insiders own 48.00% of the company’s stock.

Hedge Funds Weigh In On Pro-Dex

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Ellsworth Advisors LLC purchased a new position in shares of Pro-Dex in the third quarter valued at $1,166,000. Bank of New York Mellon Corp acquired a new position in shares of Pro-Dex during the 2nd quarter worth $678,000. Corsair Capital Management L.P. purchased a new stake in shares of Pro-Dex in the 1st quarter worth about $532,000. Apriem Advisors purchased a new stake in shares of Pro-Dex in the 3rd quarter worth about $1,385,000. Finally, First Trust Advisors LP boosted its position in shares of Pro-Dex by 26.2% in the 3rd quarter. First Trust Advisors LP now owns 7,487 shares of the medical instruments supplier’s stock worth $517,000 after buying an additional 1,553 shares in the last quarter. 15.28% of the stock is owned by institutional investors and hedge funds.

About Pro-Dex

(Get Free Report)

Pro-Dex, Inc. designs, develops and manufactures powered surgical instruments and related accessories, with a focus on devices used in orthopedic procedures. Its products include surgical handpieces and drivers, along with the components and systems that support their operation. The company also provides engineering, product development and manufacturing services to medical device companies. Its work can span the product lifecycle, from design and prototyping to production and servicing. Founded in 1978, Pro-Dex is headquartered in Irvine, California, and serves customers in the United States and international markets.

Read More

Receive News & Ratings for Pro-Dex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pro-Dex and related companies with MarketBeat.com's FREE daily email newsletter.